Stockholm-based global biopharma company Swedish Orphan Biovitrum will acquire San Diego-based private late-stage biotechnology company Arthrosi Therapeutics. Under the terms of the agreement, Sobi will pay $950 million upfront in cash to acquire Arthrosi, together with up to $550 million in cash in clinical, regulatory and sales milestones. “We are thrilled to join forces with Sobi and look forward to working together to ensure a seamless transition as they advance towards pivotal data and potential regulatory filings. The drug works by blocking URAT1, a protein involved in uric acid reabsorption, helping reduce urate levels in gout patients. Founded in 2018 by Dr. Shunqi Yan and Dr. Litain Yeh, Arthrosi has completed multiple phase 1 and 2 clinical studies and has accumulated a comprehensive intellectual property portfolio.

Source: Los Angeles Times February 05, 2026 01:32 UTC